Dr Moncef Slaoui assumed the role of Chairman, Research & Development in June 2006. He is a member of the Corporate Executive team and the Board of GlaxoSmithKline plc.
In his previous position as Senior Vice President, Worldwide business development and external alliances, he served on the R&D Executive team and spearheaded recent changes in R&D to enhance drug discovery and accelerate product development. Previously, in GSK Biologicals, he engineered the development of a robust vaccines pipeline, including Rotarix, to prevent infantile gastroenteritis, and Cervarix, to prevent cervical cancer.
Following a career in academia, he has demonstrated during his 17 years at GSK that he can create a strategic vision and then vigorously pursue it to develop new products that profoundly enhance healthcare.
Moncef earned a PhD in molecular biology and immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of immunology at the University of Mons, Belgium. He has authored more than 100 scientific papers and presentations. A citizen of Morocco and Belgium, he is fluent in English, French, and Arabic.
